Article
Dermatology
Akari Terada, Eijiro Akasaka, Hajime Nakano, Daisuke Sawamura
Summary: This article discusses three cases of pemphigus presenting with predominant skin lesions and no mucosal involvement despite high anti-Dsg3 autoantibody levels. Two cases were diagnosed as cutaneous type pemphigus and one case as pemphigus foliaceus. Weak anti-Dsg3 antibodies can induce acantholysis in the skin, but are insufficient to induce mucosal lesions.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
G. Genovese, C. A. Maronese, G. Casazza, L. Corti, L. Venegoni, S. Muratori, E. Berti, D. Fanoni, A. V. Marzano
Summary: Negativity of autoantibody titres at clinical remission based on anti-Dsg1 and anti-Dsg3 profiles at diagnosis, as well as body surface area score, are useful tools in predicting relapse in pemphigus patients.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Dermatology
Aiswarya Pradeep, Malini Eapen, Soumya Jagadeeshan, Keerthiga Kani
Summary: By using immunohistochemistry (IHC), we found that the staining patterns of desmoglein 1 (dsg 1) and desmoglein 3 (dsg 3) were correlated with autoantibody levels and clinical severity in patients with pemphigus. This method can be used as a reliable diagnostic tool.
JOURNAL OF CUTANEOUS PATHOLOGY
(2023)
Article
Endocrinology & Metabolism
M. Petruzzi, A. Romano, F. Fiori, R. Borgia, M. Contaldo, R. Serpico
Summary: Autoimmune blistering diseases are linked to SARS-CoV-2 exposure; oropharyngeal Pemphigus vulgaris is associated with the coronavirus; there is a low level of molecular mimicry between SARS-CoV-2 and Pemphigus vulgaris.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2022)
Article
Dermatology
W. L. Zhao, K. Ishii, S. Egami, Z. Xu, T. Funakoshi, H. Takahashi, A. Tanikawa, A. Ishiko, M. Amagai, J. Yamagami
Summary: This study investigated pemphigus patients who were positive for anti-Dsg IgG autoantibodies during remission, finding that some patients still had pathogenic activity of the antibodies during remission. The antibody titres decreased in remission, but did not significantly affect corticosteroid reduction and relapse rate for the patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Giulio Fortuna, Elena Calabria, Massimo Aria, Amerigo Giudice, Michele Davide Mignogna
Summary: In patients with oral-pharyngeal pemphigus vulgaris (OPV), B-cell depletion adjuvant therapy significantly impacts anti-Dsg-3 titer and B and T-cell lymphocyte subpopulations profile.
Article
Immunology
Ines Lakos Jukic, Mislav Mokos, Branka Marinovic
Summary: This retrospective study aimed to evaluate the association of HLA class II alleles and PV and to examine the impact of PV-associated HLA class II alleles on the concentration of anti-desmoglein antibodies. The results showed significantly higher frequency of HLA class II alleles in the PV patient group, as well as higher levels of antibodies against desmoglein 3 in patients with the DRB1*04:02 allele. There was no difference in the concentration of antibodies against desmoglein 1 or for the DQB1*05:03 allele. Rating: 8/10.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Ramona A. A. Eichkorn, Morna F. F. Schmidt, Elias Walter, Michael Hertl, Jens Malte Baron, Jens Waschke, Amir S. S. Yazdi
Summary: This study reveals the molecular mechanisms underlying auto-antibody-induced acantholysis in pemphigus vulgaris and identifies UVA as a cofactor for acantholysis. It demonstrates that UVA induces IL-1 secretion in keratinocytes and enhances the loss of epidermal adhesion mediated by anti-Dsg3 antibodies. These findings suggest that UVA plays a caspase-dependent exogenous role in blister formation in pemphigus vulgaris.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Dentistry, Oral Surgery & Medicine
R. Hannh, Pratibha Ramani, W. M. Tilakaratne, Gheena Sukumaran, Abilasha Ramasubramanian, Reshma Poothakulath Krishnan
Summary: Pemphigus vulgaris is an autoimmune blistering disease affecting epithelial integrity, with complex triggering pathways and a need for further treatment development.
Article
Cell Biology
Christoph Hudemann, Jochen Hoffmann, Enno Schmidt, Michael Hertl, Ruediger Eming
Summary: Pemphigus vulgaris (PV) is a potentially lethal autoimmune bullous skin disorder caused by IgG autoantibodies against desmoglein 3 (Dsg3) and Dsg1. High-dose intravenous immunoglobulins (IVIgs) have been used as an effective and safe treatment for severe, therapy-refractory PV. In a mouse model for PV, IVIg treatment resulted in alterations of T- and B-cell populations, indicating a tolerance-associated polarization in lymphatic tissue. These findings suggest that the clinical efficacy of IVIg in PV may be mediated by these distinct alterations of T- and B-cell populations.
Review
Biochemistry & Molecular Biology
Roberta Lotti, Claudio Giacinto Atene, Emma Dorotea Zanfi, Matteo Bertesi, Tommaso Zanocco-Marani
Summary: Pemphigus is a life-threatening autoimmune disease characterized by pathogenic autoantibodies targeting specific desmoglein proteins, leading to keratinocyte separation. Various disease models, including in vitro, ex vivo and in vivo mouse models, allow for testing different hypotheses regarding disease initiation and evaluating the efficacy of experimental therapies. These models also help in assessing the pathogenicity of specific Pemphigus autoantibodies and investigating previously unidentified autoantigens.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
M. Petruzzi, A. Romano, A. Baroni, R. Borgia, A. Fusco, G. Donnarumma, M. Contaldo, R. Serpico
Summary: This study found that pathogenic oral bacteria and PV autoantigens share common immunoreactive peptide sequences, supporting the hypothesis that the oral microbiome may also contribute to the pathogenesis of PV.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2022)
Article
Dermatology
Shohei Egami, Takashi Watanabe, Ayano Fukushima-Nomura, Hisashi Nomura, Hayato Takahashi, Jun Yamagami, Osamu Ohara, Masayuki Amagai
Summary: This study investigates the characteristics of autoreactive B cells in patients with pemphigus through transcriptome analysis at the single-cell level. The findings provide insights into the gene expression related to disease activity and offer potential for detecting disease-specific autoimmune cells in the future.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Review
Biology
Ambreen Rehman, Yunying Huang, Hong Wan
Summary: PV is an immunobullous condition caused by autoantibodies targeting desmosome adhesion proteins. There is no cure for the disease apart from corticosteroids and immunosuppressive agents. Understanding the molecular basis and role of DSG3 in PV is crucial for developing targeted therapies.
Article
Medicine, General & Internal
Francesco Moro, Davide Ciccone, Luca Fania, Feliciana Mariotti, Adele Salemme, Siavash Rahimi, Sabatino Pallotta, Giovanni Di Zenzo
Summary: Topical Imiquimod therapy may induce atypical pemphigus vulgaris in some patients.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
R. Asothai, Vivek Anand, Dayasagar Das, Parul Singh Antil, Sujay Khandpur, V. K. Sharma, Alpana Sharma
Article
Immunology
Dayasagar Das, Vivek Anand, Sujay Khandpur, Vinod K. Sharma, Alpana Sharma
Article
Oncology
Sandeep Appunni, Vivek Anand, Madhuram Khandelwal, Amlesh Seth, Sandeep Mathur, Alpana Sharma
Article
Cell Biology
Madhuram Khandelwal, Vivek Anand, Sandeep Appunni, Amlesh Seth, Prabhjot Singh, Sandeep Mathur, Alpana Sharma
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2018)
Review
Medical Laboratory Technology
Sandeep Appunni, Vivek Anand, Madhuram Khandelwal, Nidhi Gupta, Muni Rubens, Alpana Sharma
CLINICA CHIMICA ACTA
(2019)
Article
Oncology
Vivek Anand, Madhuram Khandelwal, Sandeep Appunni, Nidhi Gupta, Amlesh Seth, Prabhjot Singh, Sandeep Mathur, Alpana Sharma
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2019)
Article
Cell Biology
Madhuram Khandelwal, Vivek Anand, Sandeep Appunni, Amlesh Seth, Prabhjot Singh, Sandeep Mathur, Alpana Sharma
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2020)
Review
Medical Laboratory Technology
Sandeep Appunni, Muni Rubens, Venkataraghavan Ramamoorthy, Vivek Anand, Madhuram Khandelwal, Anshul Saxena, Peter McGranaghan, Yazmin Odia, Rupesh Kotecha, Alpana Sharma
Summary: Lumican, a class II SLRP, plays a crucial role in cancer biology by either promoting or inhibiting tumorigenesis depending on the specific tumor type. Its expression in the tumor microenvironment can lead to activation of pro-tumorigenic pathways in certain cancers, while demonstrating anti-tumorigenic effects in others. Further research is needed to evaluate lumican's potential as a targeted anti-cancer therapy.
CLINICA CHIMICA ACTA
(2021)
Article
Oncology
Stanley Ly, Vivek Anand, Fouad El-Dana, Khoa Nguyen, Yiming Cai, Shirong Cai, Helen Piwnica-Worms, Debasish Tripathy, Aysegul A. Sahin, Michael Andreeff, Venkata Lokesh Battula
Summary: GD2 is expressed in around 60% of primary TNBC tumors at variable levels and is associated with worse overall survival of patients with TNBC. Treatment with dinutuximab significantly decreased adhesion and migration of TNBC cells, inhibited mTOR signaling, and reduced tumor growth in both cell-line xenografts and PDX models. Our data provide proof-of-concept for the critical role of GD2 in BCSCs and demonstrate the potential of dinutuximab as a novel therapeutic approach for TNBC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Sandeep Appunni, Muni Rubens, Venkataraghavan Ramamoorthy, Vivek Anand, Madhuram Khandelwal, Alpana Sharma
Summary: Biglycan, as a class I SLRP, is a key component of the ECM involved in scaffolding collagen fibrils and mediating cell signaling. Dysregulation of its expression can lead to various clinical conditions including metabolic disorders, inflammatory disorders, musculoskeletal defects, and malignancies. Biglycan interacts with TLR-2 and TLR-4 on immune cells to induce inflammation, and its dysregulation is also observed in inflammatory metabolic conditions and cancer, where high expression levels facilitate tumor growth and metastasis.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2021)
Review
Multidisciplinary Sciences
Claire Shao, Vivek Anand, Michael Andreeff, Venkata Lokesh Battula
Summary: TNBC is a heterogeneous disease characterized by lack of hormone receptor expression, with high recurrence and distant metastasis rates. Targeting breast cancer stem-like cells is an effective strategy for preventing metastatic spread and enhancing sensitivity to chemotherapy.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
(2022)
Article
Oncology
Appalaraju Jaggupilli, Stanley Ly, Khoa Nguyen, Vivek Anand, Bin Yuan, Fouad El-Dana, Yuanqing Yan, Zoe Arvanitis, Danthasinghe Waduge Badrajee Piyarathna, Nagireddy Putluri, Helen Piwnica-Worms, Henry Charles Manning, Michael Andreeff, V. Lokesh Battula
Summary: This study demonstrates that metabolic stress induces the GD2(+) BCSC phenotype in triple-negative breast cancer (TNBC) and highlights the role of glutamine in this phenotype. Inhibiting glutamine transporters can reduce BCSC characteristics in TNBC cells, suggesting a potential complementary approach to conventional chemotherapy.
BRITISH JOURNAL OF CANCER
(2022)
Meeting Abstract
Oncology
Fouad El-Dana, Bin Yuan, Stanley Ly, Vivek Anand, Venkata Lokesh Battula
Meeting Abstract
Oncology
Eriko Katsuta, Vivek Anand, Li Yan, Subhamoy Dasgupta, Kazuaki Takabe
Meeting Abstract
Immunology
Dayasagar Das, Vivek Anand, Parul Singh Antil, Sujay Khandpur, V. K. Sharma, Alpana Sharma
JOURNAL OF IMMUNOLOGY
(2015)